title: [Pain killers--killing the pain or the patient?].
abstract: Over the last years, the coxibes were widely used as potent and well tolerated pain killers. This was in part due to the better gastrointestinal tolerability of the coxibes. On the other hand the higher cox-2 selectivity is consistent with a higher cardio-vascular event rate in patients with coxibe therapy which has been demonstrated by several studies. Side effects are probably caused by the interaction of the following factors: impact on thrombocytes, coagulation, blood vessel physiology, and blood pressure. Of note, the reported cardio-vascular adverse event rates in trials evaluating coxibes and older non-steroidal anti-inflammatory drugs was very low. Furthermore, there were no difference in fatal event rates. This underscores the need to carefully deliberate about the beneficial and potentially harmful use of these drugs. In daily practice it therefore might be suitable to still use these drugs to alleviate pain in selected patients.
authors.affiliation: Kardiologische Klinik, Universitätsspital Basel. .
authors.forename: M J
authors.initials: MJ
authors.lastname: Zellweger
authors.forename: M E
authors.initials: ME
authors.lastname: Pfisterer
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors